Xconomy

MAY 31, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors. He co-founded Arcturus and is the company’s largest shareholder, with a 13.7 percent stake.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

APRIL 5, 2018

As a showdown stockholders meeting draws near for San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), a proxy battle is boiling down to an argument over who represents the best interests of shareholders in the tiny RNA drug company. In an April 3 letter addressed to the company’s four board members, Arcturus co-founder and ex-CEO Joseph E.

Arcturus 49

Arcturus San Diego Company Companies 49

Xconomy

MARCH 29, 2018

The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. In a lawsuit filed Tuesday (see below) and in an open letter to shareholders issued Wednesday , the Arcturus (NASDAQ: ARCT ) board ­says a pattern of alleged misconduct, deceit, and failed leadership by Payne led to his termination on January 25. Payne, who.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

MAY 22, 2018

After postponing a May 7 shareholder vote in a power struggle for control of San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), the company’s board of directors has set a new date for its showdown with ousted CEO Joseph Payne. In a statement Monday, Arcturus said it has rescheduled its special shareholder meeting for 10 a.m.

Arcturus 40

Arcturus San Diego Blogging Startup 40

Xconomy

APRIL 17, 2020

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84

Equity Activity Marketing Company 84

Xconomy

JANUARY 3, 2019

As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.” San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs.

Develop 65

Develop Development San Diego Arcturus 65

Xconomy

FEBRUARY 9, 2018

The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers.

Help 58

Help Develop Development Arcturus 58

Xconomy

JUNE 1, 2018

For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks off today. Many ASCO attendees will zero in on potential cancer drug combinations.

News 55

News Arcturus San Diego Blogging 55

Xconomy

MARCH 30, 2018

If the recent IPO activity seems to be on overdrive, it’s not your imagination. The number of companies filing to go public in the U.S. in the first quarter was up 44 percent compared to the same period a year ago, according to data compiled by consulting and accounting firm EY.

Activity 52

Activity Report Marketing Company 52

Xconomy

MARCH 2, 2018

Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6

Funding 52

Funding Report Startup Venture Capital 52